Article
Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18).
Anticancer research - 1 Mar 2023
Maeda Akimitsu, Ando Hitoshi, Irie Kei, Hashimoto Naoya, Morishige Jun-Ichi, Fukushima Shoji, Ebi Hiromichi, Uchida Kosaku, Iwata Hiroji, Sawaki Masataka
Abstract excerpt
BACKGROUND/AIM: Abemaciclib, an oral anticancer drug used in the treatment of breast cancer, is metabolised to its active forms - M2, M20 and M18; these forms have a potency similar to that of the parent drug. Abemaciclib and its active metabolites are reportedly transported by P-glycoprotein and breast cancer resistance protein (BCRP). We previously reported that the ABCB1 2677G>T/A homozygous type is associated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.